Takeda and Lundbeck submit New Drug Application (NDA) for vortioxetine in Japan for the treatment of Major Depressive Disorder (MDD)
· NDA submission highlights four key studies involving approximately 1,400 patients, including the pivotal phase III study conducted in Japan · Pivotal phase III study demonstrated positive results of vortioxetine as compared to placebo for the treatment of MDD in Japanese adults Valby, Denmark and Osaka, Japan, 28 September 2018 - H. Lundbeck A/S (Lundbeck) and its partner Takeda Pharmaceutical Company Limited (Takeda) today announced the submission of a New Drug Application (“NDA”) to the Japanese Ministry of Health, Labour and Welfare for vortioxetine for the treatment of Major